Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
33 hedge funds and large institutions have $8.5M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 6 closing their positions.
11% less funds holding
Funds holding: 37 → 33 (-4)
40% less capital invested
Capital invested by funds: $14.2M → $8.5M (-$5.67M)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.6K |
| 3 |
Man Group
London,
United Kingdom
|
+$10.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.44K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$794 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$54.8K |
| 2 |
Renaissance Technologies
New York
|
-$50.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$32.9K |
| 4 |
State Street
Boston,
Massachusetts
|
-$22.8K |
| 5 |
Morgan Stanley
New York
|
-$8.85K |
SGTX Hedge Fund Activity: Q3 2022 in Review
33 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q3 2022, worth a combined $8.5M — down 40% from $14.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SGTX and 2 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $38.5K. The largest seller was Millennium Management, cutting an estimated $54.8K.
- 33 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q3 2022, down from 37 in Q2 2022.
- Funds reported $8.5M of Sigilon Therapeutics, Inc. Common Stock stock for Q3 2022, down 40% quarter-over-quarter.
- 2 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of -4 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $38.5K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $54.8K sold.
Based on aggregated 13F filings for Q3 2022.